New drug plus rapamycin and chemo for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 trial tests whether a new HER2-targeting drug (inetetamab) combined with rapamycin and standard chemotherapy works better than the control approach for HER2-positive metastatic breast cancer. It is mainly for people whose tumor genetics suggest a specific “PAM pathway” problem.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman and older than 18
- Your breast cancer is HER2-positive based on test results (IHC and/or FISH)
- Your cancer is confirmed invasive breast cancer that has come back or spread (metastatic)
- Your tumor has a mutation in the PI3K/Akt/mTOR pathway genes (related to the PAM pathway)
- You can do activities at about a normal level (ECOG score 0–2) and expect to live at least 6 months
- Your heart and organ tests are good enough to start treatment (heart pumping strength LVEF at least 50% and acceptable blood counts/liver tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
This study tests a drug called inetetamab as a first treatment for HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see how well it works in real-world settings.
This Phase 3 study tests giving trastuzumab and pertuzumab as additional (adjuvant) treatment after you had those same medicines before surgery but still had remaining cancer. It may help lower the chance that HER2-positive breast cancer comes back.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.